CA2651367A1 - Methods of enriching fetal cells - Google Patents

Methods of enriching fetal cells Download PDF

Info

Publication number
CA2651367A1
CA2651367A1 CA002651367A CA2651367A CA2651367A1 CA 2651367 A1 CA2651367 A1 CA 2651367A1 CA 002651367 A CA002651367 A CA 002651367A CA 2651367 A CA2651367 A CA 2651367A CA 2651367 A1 CA2651367 A1 CA 2651367A1
Authority
CA
Canada
Prior art keywords
cells
agent
cell
binds
fetal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651367A
Other languages
English (en)
French (fr)
Inventor
Ralph Michael Boehmer
Richard Allman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetic Technologies Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651367A1 publication Critical patent/CA2651367A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002651367A 2005-05-11 2006-05-11 Methods of enriching fetal cells Abandoned CA2651367A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US67974505P 2005-05-11 2005-05-11
US60/679,745 2005-05-11
US68974505P 2005-06-09 2005-06-09
US60/689,745 2005-06-09
US72536505P 2005-10-11 2005-10-11
US60/725,365 2005-10-11
PCT/AU2006/000617 WO2006119569A1 (en) 2005-05-11 2006-05-11 Methods of enriching fetal cells

Publications (1)

Publication Number Publication Date
CA2651367A1 true CA2651367A1 (en) 2006-11-16

Family

ID=37396103

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651367A Abandoned CA2651367A1 (en) 2005-05-11 2006-05-11 Methods of enriching fetal cells

Country Status (5)

Country Link
US (2) US20090305236A1 (enExample)
EP (1) EP1886138A4 (enExample)
JP (1) JP2008543277A (enExample)
CA (1) CA2651367A1 (enExample)
WO (1) WO2006119569A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112324714A (zh) * 2020-11-02 2021-02-05 上海志力泵业制造有限公司 一种安装简单的代潜水排污泵

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070196820A1 (en) * 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
WO2008081451A2 (en) * 2007-01-03 2008-07-10 Monaliza Medical Ltd. Methods and kits for analyzing genetic material of a fetus
WO2008132753A2 (en) * 2007-05-01 2008-11-06 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for detecting fetal cells in the maternal blood
CA2752838A1 (en) * 2008-02-18 2009-08-27 Genetic Technologies Limited Cell processing and/or enrichment methods
ES2533861T3 (es) * 2009-01-07 2015-04-15 Arcedi Biotech Aps Enriquecimiento e identificación de células fetales en sangre materna y ligandos para tal uso
EP2421955A4 (en) 2009-04-21 2012-10-10 Genetic Technologies Ltd METHODS OF OBTAINING F TAL GENETIC MATERIAL
US20120115167A1 (en) * 2009-04-22 2012-05-10 Clinical Genomics Pty. Ltd. Method and apparatus for isolating a target bioentity from a biological sample
EP2516677B1 (en) 2009-12-23 2014-11-26 Genetic Technologies Limited Methods of enriching and detecting fetal nucleic acids
CN102762712A (zh) 2010-01-21 2012-10-31 百赛普有限公司 稀有细胞的磁性分离
US20130130930A1 (en) * 2011-11-17 2013-05-23 Bhairavi Parikh Methods and devices for obtaining and analyzing cells
CN106967801A (zh) * 2017-03-28 2017-07-21 华子昂 一种人类hla区域基因拷贝数变异检测方法
JP7062901B2 (ja) * 2017-09-22 2022-05-09 東ソー株式会社 目的細胞の検出方法
US20220088071A1 (en) * 2018-11-30 2022-03-24 The Trustees Of The University Of Pennsylvania A BW6 Specific CAR Designed To Protect Transplanted Tissue From Rejection
JP7684914B2 (ja) 2019-06-07 2025-05-28 アルセディ バイオテック エーピーエス Ｆａｃｓを用いた胎児細胞の単離
AU2020315211A1 (en) * 2019-07-15 2022-02-10 A. Menarini Biomarkers Singapore Pte. Ltd. Compositions and methods for isolating, detecting, and analyzing fetal cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4769319A (en) * 1985-05-31 1988-09-06 Salk Institute Biotechnology Industrial Associates, Inc. Nucleic acid probes for prenatal sexing
US5192659A (en) * 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5153117A (en) * 1990-03-27 1992-10-06 Genetype A.G. Fetal cell recovery method
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) * 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) * 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
AU4685593A (en) * 1992-07-17 1994-02-14 Aprogenex, Inc. Enriching and identyfying fetal cells in maternal blood for in situ hybridization
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5378725A (en) * 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en) * 1993-08-25 1995-08-15 Eli Lilly And Company Methods of inhibiting vascular restenosis
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
CA2133815A1 (en) * 1993-10-12 1995-04-13 Jeffrey Alan Dodge Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US5804380A (en) * 1993-11-12 1998-09-08 Geron Corporation Telomerase activity assays
US5480906A (en) * 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
ATE228026T1 (de) * 1995-03-08 2002-12-15 Bioseparations Inc Methode zur erreicherung von populationen seltener zellen
WO1997015687A1 (en) * 1995-06-07 1997-05-01 Geron Corporation Telomerase activity assays
JP3703569B2 (ja) * 1996-04-02 2005-10-05 ソニー株式会社 光記録媒体及びその記録再生方法、記録再生装置
FI990655A7 (fi) * 1996-10-01 1999-06-01 Geron Corp Ihmistelomeraasin katalyyttinen alayksikkö
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
US6667340B1 (en) * 1998-06-26 2003-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Inhibitors of phosphatidyl myo-inositol cycle
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6403588B1 (en) * 2000-04-27 2002-06-11 Yamanouchi Pharmaceutical Co., Ltd. Imidazopyridine derivatives
US6813008B2 (en) * 2002-06-10 2004-11-02 Palantyr Research, Llc Microdissection optical system
WO2004033707A2 (en) * 2002-10-07 2004-04-22 Marligen Biosciences, Inc. Extraction of dna from biological samples
HRP20060073B1 (hr) * 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
US8044057B2 (en) * 2003-12-09 2011-10-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods for suppressing an immune response or treating a proliferative disorder
US7439062B2 (en) * 2004-12-23 2008-10-21 Biocept, Inc. Beads for capturing target cells from bodily fluid

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112324714A (zh) * 2020-11-02 2021-02-05 上海志力泵业制造有限公司 一种安装简单的代潜水排污泵

Also Published As

Publication number Publication date
JP2008543277A (ja) 2008-12-04
US20130295561A1 (en) 2013-11-07
EP1886138A1 (en) 2008-02-13
US20090305236A1 (en) 2009-12-10
EP1886138A4 (en) 2009-04-15
WO2006119569A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
US20130295561A1 (en) Methods of enriching fetal cells
Vaziri et al. Loss of telomeric DNA during aging of normal and trisomy 21 human lymphocytes
Hviid et al. HLA-G allelic variants are associated with differences in the HLA-G mRNA isoform profile and HLA-G mRNA levels
Bedi et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia
Plotkin et al. Critical role for CXCR4 signaling in progenitor localization and T cell differentiation in the postnatal thymus
Corcoran et al. The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells
Ariga et al. Kinetics of fetal cellular and cell‐free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis
Castellana et al. Maternal obesity alters uterine NK activity through a functional KIR2DL1/S1 imbalance
EP2250497B1 (en) Cell processing and/or enrichment methods
Varla-Leftherioti et al. Lack of the appropriate natural killer cell inhibitory receptors in women with spontaneous abortion
US9447467B2 (en) Methods for obtaining fetal genetic material
US5635365A (en) Noninvasive diagnosis for allograft rejection
Berry et al. Association of maternal histocompatibility at class II HLA loci with maternal microchimerism in the fetus
Nelson Microchimerism and human autoimmune diseases
AU738401B2 (en) Prenatal diagnostic methods
Webster et al. The myoblast defect identified in Duchenne muscular dystrophy is not a primary expression of the DMD mutation: clonal analysis of myoblasts from five double heterozygotes for two X-linked loci: DMD and G6PD
Dobrovolsky et al. Evaluation of Macaca mulatta as a model for genotoxicity studies
US20110256121A1 (en) Methods and kits for diagnosing or monitoring autoimmune and chronic inflammatory diseases
Muench et al. Transplantation of a fetus with paternal Thy-1+ CD34+ cells for chronic granulomatous disease
Pramoonjago et al. Genotypic, immunophenotypic and clinical features of Thai patients with paroxysmal nocturnal haemoglobinuria
US20130267613A1 (en) Molecular-determinant based typing of kir alleles and kir-ligands
US7960125B2 (en) Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression
Grant et al. Diagnosis of ataxia telangiectasia with the glycophorin A somatic mutation assay
US10761098B2 (en) Methods and tools for Vel blood group typing
Kinsella et al. CD52/GPI− T-Cells Are Enriched for Alloreactive Specificity and Predict Acute Graft-Versus-Host-Disease After Stem Cell Transplantation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20151218